Nanexa

Nanexa is a clinical-stage biotech company on a mission to redefine injectable medicines through its unique nanoengineering platform, PharmaShell®. The company has achieved significant validation through strategic partnerships with industry leaders like Novo Nordisk and AstraZeneca and is progressing proprietary assets toward clinical proof-of-concept. Its dual business model combines internal pipeline development with high-value technology licensing, aiming to capture value in the expansive long-acting injectables market.

PharmaShell® is a drug delivery platform that uses Atomic Layer Deposition (ALD) to apply ultra-thin, tunable inorganic coatings onto drug particles, enabling precise, sustained release over weeks to months from a single injection.

Nanexa competes with polymer-based depot technologies (e.g., MedinCell) and large pharma's internal capabilities. Its primary differentiation is the unique, atomic-level precision of its ALD-based PharmaShell® coating, which offers potential advantages in drug loading and release profile control.